Diazepam is commonly used to treat acute childhood seizures, but difficulty gaining intravenous access and variability of absorption after rectal administration can limit its efficacy. Midazolam is a water soluble benzodiazepine that has a rapid onset of action after intranasal or buccal administration and provides an alternative to diazepam in the control of acute childhood seizures. Methods: A literature search was performed to identify papers comparing the efficacy and tolerability of midazolam and diazepam in the management of childhood seizures. Results: Intranasal or buccal midazolam are at least as effective as rectal or intravenous diazepam in controlling acute childhood seizures. In all robust studies reporting a significant difference, time to gain seizure control was shorter in patients treated with midazolam than those treated with diazepam, predominantly due to shorter drug administration time. The incidence of seizure recurrence was lower in patients treated with midazolam than diazepam. Respiratory depression was uncommon in both groups. Conclusion: Intranasal or buccal midazolam provides a safe, effective and acceptable alternative to intravenous or rectal diazepam in the management of acute childhood seizures. (Hong Kong j.emerg.med. 2010;17:196-204) 
Introduction
The incidence of epilepsy in developed societies has been estimated to range from 40 to 70 cases per 100,000 persons per year. [1] [2] [3] [4] In the UK, the overall incidence is 66.3 cases per 100,000 persons per year. 5 Almost half of these cases occur in children. 6 Most childhood seizures are brief and resolve without treatment but in those that do not, early use of effective medication that reduces seizure duration has been shown to decrease morbidity and mortality. 7 However, approximately 10% to 20% of seizures are refractory to currently used medication. 6 Diazepam is a benzodiazepine that has been extensively used in the management of epileptic seizures for four decades. 8 It has a rapid onset of action (usually 3-5 minutes) and a short duration of action (20-30 minutes) . 9 Rectal diazepam is generally regarded as the gold-standard of prehospital management of acute childhood seizures. 10 Because diazepam accumulates in fat stores, repeated doses can lead to a prolonged period of sedation. 10 Cardio-respiratory depression and hypotension can also occur. 6 Administration of rectal diazepam can be embarrassing and awkward and absorption is variable. 11 First pass metabolism can lead to significant drug inactivation before therapeutic effects are achieved. 12 Midazolam is an imidazobenzodiazepine with sedative, amnesic, anxiolytic, muscle relaxant and anticonvulsant properties. 13 It is more potent than diazepam and has a rapid onset of action (2-3 minutes).
14 Midazolam can be administered intravenously, intramuscularly, rectally, buccally or intranasally. For acute childhood seizures, intranasal and buccal routes provide rapid absorption into the systemic circulation over a large surface area and are less invasive than rectal anticonvulsant administration. 15, 16 Midazolam's short half-life also means it has a lower potential than diazepam for drug accumulation and prolonged sedation. 11, 13, 16 This clinical topic review aims to compare the efficacy and tolerability of diazepam and midazolam in the control of paediatric seizures.
Literature review

Search strategy
The following listed were accessed through Athens login via the Dialog Datastar interface. Science Direct, Proquest and ejournals were accessed and searched directly ( Figure 1 ).
MEDLINE 1950 to date
The search was conducted on 15 October 2008. Search terms were chosen based on previous Best Evidence Topics: Midazolam OR Diazepam OR Benzodiazepine OR Fit OR Seizure OR Convulsion OR Epilepsy. Terms were exploded to maximise the chance of success. Results were limited to English, as translation facilities were not available, and limited to children for relevance to the chosen topic.
The search returned 332 results. The titles and abstracts of these were reviewed to identify journal articles relevant to the clinical review topic. A total of 21 relevant articles were selected for analysis.
EMBASE 1974 to date
Search terms similar to those for the MEDLINE search were chosen. Duplicates were removed from the two databases. The search returned 1030 results. Two new articles were found. On review, one was considered relevant to the search and was added to the analysis.
COCHRANE
The search was conducted on 15 October 2008. Search terms were similar to those for the MEDLINE search. The search returned 43 hits, one of which was considered relevant.
Cross references
All selected articles, reviews and letters to the editors were reviewed for relevant cross references. Two case reports were added to the review and two articles related to the pharmacology of benzodiazepines were studied.
Web resources
The following web resources were accessed: 
Grey literature
Several authors involved in the study of midazolam versus diazepam were contacted and two ongoing studies were identified: one in Kenya Medical Research Institute, Kilifi, headed by Simon Muchohi; and another in Salt Lake City, USA, headed by Maija Holsti. Data collection for the latter was designed to compare intranasal midazolam with diazepam.
The International Clinical Trials Registry Platform (www.who.int/ictrp/en/) and The National Research Register (www.controlled-trials.com) were searched for any unpublished trials. No study was found.
Inclusion and exclusion criteria
All studies in which drugs were administered were included, even when drug administration occurred at the beginning of the seizure. No differentiation was made between first episode or repeated seizures. Studies of patients with status epilepticus were excluded from this review. Level 3 and 4 studies were excluded after analysis, due to the poor quality of evidence.
Results
A total of 24 papers comparing midazolam with diazepam in acute childhood seizures were found. Two of the papers were level 3, one was a retrospective study, while eleven papers were level 4 case reports or uncontrolled cohort studies and these were not included due to their poor quality of evidence. The results of the remaining 10 papers are summarised (Tables 1-3) .
Discussion
An ideal anticonvulsant should be safe, effective, easy to administer, rapid-acting and cost-effective. Diazepam has been used in the management of epilepsy and other convulsive syndromes for the past four decades and controls seizures in 60-80% of the cases. 27 However, orally administered preparations of diazepam are too slow acting for acute use and intramuscular formulations have variable absorption. 28, 29 In acute seizures, therefore, intravenous or rectal preparations of diazepam are usually used, but gaining intravenous access in convulsing children is difficult and rectal drug administration may be embarrassing.
Of the four randomised, controlled trials reviewed that compared buccal midazolam with rectal diazepam, Mpimbaza et al and McIntnyre et al found that significantly more children achieved seizure control within 10 minutes when treated with midazolam than with diazepam, while Baysun et al and Scott et al found no difference between treatments. [17] [18] [19] [20] Seizure recurrence was significantly less common in children treated with midazolam than diazepam, in the two studies reporting on it. 17, 18 In all studies, respiratory depression was uncommon in either treatment group. [17] [18] [19] [20] Three studies were reviewed that compared intranasal midazolam with rectal diazepam. [21] [22] [23] Bhattacharyya et al and Fisgin et al found that more children achieved seizure control within 10 minutes with midazolam than diazepam, although in the Bhattacharyya et al study, the difference was not statistically significant; and in the Holsti et al study, seizure control within 10 minutes was not reported. 21, 22 The time to seizure cessation was significantly shorter in patients treated with midazolam than diazepam, in the two studies reporting on it.
22,23
The Bhattacharyya et al study examined the time to drug administration and found it to be significantly shorter in the midazolam group. 22 No significant difference was found in the rate of seizure recurrence within one hour. 21 Holsti et al showed that respiratory depression was significantly less common in children treated with midazolam than diazepam. 21 In the other studies, respiratory depression was uncommon in either group. 22, 23 Three studies in this review compared intranasal midazolam with intravenous diazepam. [24] [25] [26] Lahat et al and Mittal et al found that the mean time to seizure cessation was significantly lower in children treated with midazolam than diazepam. 25, 26 Although Mahmoudian et al found that seizures were controlled an average of 40 seconds faster with diazepam treatment, they did not include the time taken to gain intravenous access, 24 and therefore does not reflect the clinical reality of the situation. The other studies both reported that drug administration was significantly faster in children treated with midazolam, 25, 26 suggesting that the difference in the results between these studies may be due to these methodological differences. No significant adverse events, including respiratory depression, were reported in these studies. [24] [25] [26] Overall, this literature review has demonstrated that midazolam is at least as effective as diazepam in controlling acute childhood seizures. Seizure control was gained as rapidly or significantly more rapidly in children treated with midazolam than those treated with diazepam in all studies except one, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] and this study was flawed as it did not take into account the time required to gain intravenous access in order to administer diazepam. 24 Notably, the time required to administer midazolam, by either the intranasal or intramuscular route, was significantly faster than the time required to administer intravenous diazepam in all studies that examined it. 22, 25, 26, 32 Diazepam rectal preparation of 10 mg in 2.5 ml costs £1.96 whereas the cost of 10 mg midazolam, prepared in 1 ml solution for buccal administration (Epistatus), marketed by special products company in the UK, is Midazolam is not licensed in the UK for use in controlling seizures in children. A survey of five European hospitals, which analyzed 2262 prescriptions administered to 624 children, found that almost half of all drug prescriptions (1036; 46%) were either unlicensed or off label. Of these 1036, 872 were off label and 164 were unlicensed. On the whole, over half of the patients (421; 67%) received an unlicensed or off label prescription. 33 NICE guidelines for the treatment of prolonged and repeated seizures in the community recommend that buccal midazolam should be used according to an agreed protocol drawn up by the specialist and only used following training (www. nice.org.uk). There are several NHS (National Health Service) trusts in the UK which have drawn up protocol for the use of buccal midazolam by clinicians, families and/or carers.
On the basis of available evidence from this clinical topic review and in accordance with the NICE and APLS guidelines, I have suggested a protocol for the use of midazolam in controlling seizures in children (Appendix). It is, however, important to note that midazolam is not currently licensed for this use in the UK and therefore local consensus from the specialist team and ethics committee should be sought prior to its use.
Conclusion
In conclusion, intranasal or buccal midazolam provides a safe, effective and convenient alternative to intravenous or rectal diazepam in the management of acute childhood seizures.
